

## **Tobramycin**

Tobramycin dosing is weight based; ensure accuracy of documented weight before administration		
Restricted Antimicrobial See CUH Antimicrobial Guidelines on Eolas for further information		
CAUTION: High Administration Risk Rating		
Form	80mg per 2mL vial	
Reconstitution	Already in solution	
Compatibility & Stability	Sodium Chloride 0.9% Glucose 5%	
Administration	Multiple Daily Dosing	Once Daily Dosing
	IV Infusion Dilute in 50 - 100mL compatible fluid and give over 20 - 60 minutes.  IV Injection Slow Injection over 3 - 5 minutes May be diluted to 10 mL with sodium chloride 0.9% or glucose 5% to facilitate slow administration	IV Infusion Dilute to 100mL compatible fluid and give over 60 minutes.  IV Injection Not recommended
	IM Injection Give by deep IM injection	IM Injection Not recommended
Monitoring	Plasma level monitoring recommended; refer to CUH antimicrobial guidelines on Eolas for further information.  • Monitor renal function before starting and during treatment.  • Monitor auditory and vestibular function during treatment.	
Extravasation	Extravasation may cause damage due to low pH.	
Additional Information	<ul> <li>To avoid excessive dosage in obese patients (where Actual Body Weight is more than 120% of Ideal Body Weight), use Adjusted Body Weight to calculate dose – see the CUH Antimicrobial Guidelines on Eolas for guidance. Dose should be rounded to nearest vial.</li> <li>Duration should be kept as short as possible (usual maximum duration 5-7 days) to minimise risk of otoxoticity and nephrotoxicity.</li> </ul>	

Information provided relates to Tobramycin manufactured by Pfizer, Flynn Pharma and Mylan.